🔗 Share this article

This year's Nobel Prize in Physiology or Medicine has been awarded for transformative findings that clarify how the body's defense network targets dangerous pathogens while protecting the healthy tissues.

A trio of esteemed researchers—from Japan Shimon Sakaguchi and American experts Mary Brunkow and Dr. Ramsdell—share this honor.

Their research uncovered unique "sentinels" within the defense system that remove rogue immune cells that could attacking the organism.

The findings are now enabling innovative treatments for autoimmune diseases and cancer.

These laureates will divide a prize fund valued at 11 million Swedish kronor.

Decisive Findings

"Their work has been essential for comprehending how the body's defenses operates and why we don't all suffer from severe autoimmune diseases," commented the head of the award panel.

The team's research explain a fundamental mystery: How does the defense system protect us from countless infections while keeping our own tissues unharmed?

Our immune system employs white blood cells that search for indicators of disease, including pathogens and bacteria it has not met before.

These cells utilize detectors—called receptors—that are generated randomly in countless combinations.

That provides the immune system the capacity to combat a broad range of threats, but the randomness of the process inevitably creates immune cells that can attack the body.

Protectors of the Body

Researchers previously understood that a portion of these harmful white blood cells were destroyed in the thymus—the site where immune cells mature.

The latest award recognizes the identification of regulatory T-cells—described as the immune system's "peacekeepers"—which travel through the system to neutralize any defenders that attack the healthy cells.

We know that this process fails in autoimmune diseases such as type-1 diabetes, MS, and RA.

The Nobel panel stated, "The discoveries have established a novel area of investigation and accelerated the development of innovative therapies, for example for tumors and immune disorders."

Regarding cancer, T-regs block the system from fighting the tumor, so research are focused on reducing their numbers.

For self-attack disorders, experiments are exploring increasing T-reg cells so the body is no longer being harmed. A similar approach could also be effective in reducing the risks of organ transplant rejection.

Innovative Studies

Prof Shimon Sakaguchi, from Osaka University, conducted experiments on rodents that had their thymus removed, leading to autoimmune disease.

He demonstrated that injecting defense cells from healthy animals could prevent the disease—suggesting there was a mechanism for blocking defenders from harming the host.

Dr. Brunkow, from the Institute for Systems Biology in Seattle, and Fred Ramsdell, currently at Sonoma Biotherapeutics in San Francisco, were investigating an inherited autoimmune disease in mice and people that led to the identification of a genetic factor critical for how regulatory T-cells operate.

"Their groundbreaking research has revealed how the immune system is kept in check by regulatory T cells, preventing it from accidentally targeting the healthy cells," said a leading physiology expert.

"This research is a remarkable illustration of how basic biological research can have far-reaching consequences for public health."